| Synonym |
| Thai / English name |
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside R-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 1 microgram/mLDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Induction potential of 1 microgram/mL ginsenoside S-Rh2 on activities of CYP1A2, CYP2B6 and CYP3A4/5 in three different lots of cryopreserved human hepatocytes. Fold increase enzyme activity in each CYP were 0.961 +/- 0.0621, 1.023 +/- 0.0650, and 0.881 +/- 0.114, respectively.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside S-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10 microgram/mLDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Induction potential of 10 microgram/mL ginsenoside S-Rh2 on activities of CYP1A2, CYP2B6 and CYP3A4/5 in three different lots of cryopreserved human hepatocytes. Fold increase enzyme activity in each CYP were 1.04 +/- 0.0633, 1.13 +/- 0.191, and 0.860 +/- 0.0586, respectively.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : BST24 (a purified dry extract of ginseng)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : BST204 weakly inhibited UGT1A1, UGT1A9, and UGT2B7 activities with IC50 values of 14.5, 26.6, and 31.5 microgram/mL, respectively.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside S-Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Ginsenoside S-Rg3 inhibited UGT1A1, UGT1A9, and UGT2B7 activities, with IC50 values of 89.0, 14.9, 21.5 micromolar, respectively.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside R-Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark :
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside S-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Ginsenoside S-Rh2 inhibited UGT1A1 activities, with IC50 values of 54.5 micromolar.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Ginsenoside R-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark :
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : BST204 (a purified dry extract of ginseng)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 400 mg/kgDuration : -Type of interaction : PharmacokineticsInteraction with drug : Irinotecan*/Camptothecin-11/CPT-11Dose/Conc.(drug) : -Result : NegativeRemark : Irinotecan 20 mg/kg (intraperitoneal administration).
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Zidovudine*/AZT/ZDV/AzidothymidineDose/Conc.(drug) : -Result : PositiveRemark : Type of experiment = human liver microsomesNote : The results showed the inhibition of Rg3 towards human liver microsomes-catalyzed zidovudine (AZT) glucuronidation in a concentration-dependent behaviour.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 25 microgram/mlDuration : 5 minutesType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Details of the standardized Ginseng extracts: 0.44% Eleutheroside E, 0.25% Eleutheroside B. - Results: The degree of CYP3A4 inhibition of Ginseng was 14.8%Note : The effects of complementary and alternative medicine (CAM) on CYP3A4-mediated metabolism of midazolam and docetaxel were determined in human liver microsomes (HLM), using liquid-chromatography coupled to tandem mass spectrometry (LC-MS/MS).
